Erasca Faces Class Action Lawsuit, Investors Can Claim Damages
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Source: PRnewswire
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Erasca, Inc., aiming to recover damages for investors who purchased its securities between January 14, 2025, and April 26, 2026, highlighting potential legal risks facing the company.
- Allegations Overview: The complaint alleges that the defendants made false and misleading statements and failed to disclose material facts during the class period, which may have led investors to make erroneous decisions under conditions of asymmetric market information, thereby impacting their investment returns.
- Investor Participation Opportunity: Affected investors have until August 10, 2026, to apply to be lead plaintiffs, indicating that this case provides an avenue for investors to engage in legal proceedings and seek compensation, enhancing oversight of corporate governance.
- Fee Arrangement for Investors: Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis, meaning they will only charge fees after a successful claim, which reduces the financial burden on investors and encourages more victims to participate in the lawsuit.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ERAS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ERAS
Wall Street analysts forecast ERAS stock price to fall
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 14.430
Low
2.00
Averages
5.50
High
11.00
Current: 14.430
Low
2.00
Averages
5.50
High
11.00
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Lawsuit Announced for Erasca, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Erasca (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, with a deadline of August 10, 2026, for those wishing to serve as lead plaintiff, potentially allowing for compensation.
- Legal Violations Allegations: The lawsuit alleges that Erasca, along with its CEO and CFO, violated federal securities laws by making false and misleading statements regarding its lead oncology drug candidate, ERAS-0015, throughout the class period, resulting in investor losses.
- Potential Compensation Mechanism: Investors joining the class action will not incur out-of-pocket fees, as attorney costs will be covered through a contingency fee arrangement, thereby reducing financial barriers and encouraging broader participation from affected investors.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its extensive experience and success in handling similar cases, which enhances investor confidence in their representation.
See More
Erasca Faces Class Action Lawsuit, Investors Can Claim Damages
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Erasca, Inc., aiming to recover damages for investors who purchased its securities between January 14, 2025, and April 26, 2026, highlighting potential legal risks facing the company.
- Allegations Overview: The complaint alleges that the defendants made false and misleading statements and failed to disclose material facts during the class period, which may have led investors to make erroneous decisions under conditions of asymmetric market information, thereby impacting their investment returns.
- Investor Participation Opportunity: Affected investors have until August 10, 2026, to apply to be lead plaintiffs, indicating that this case provides an avenue for investors to engage in legal proceedings and seek compensation, enhancing oversight of corporate governance.
- Fee Arrangement for Investors: Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis, meaning they will only charge fees after a successful claim, which reduces the financial burden on investors and encourages more victims to participate in the lawsuit.
See More
Erasca, Inc. Shareholder Class Action Notice Issued
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Erasca, Inc. (NASDAQ:ERAS), encouraging those who purchased shares between January 14, 2025, and April 26, 2026, to contact the firm regarding potential lead plaintiff appointment for recovery.
- Allegations Overview: The complaint alleges that during the class period, defendants made materially false and/or misleading statements and failed to disclose that ERAS-0015's preclinical data was improperly compared to Revolution Medicines, Inc., risking patent violations and impacting investor trust and stock performance.
- Critical Deadline: Shareholders must register by August 10, 2026, to seek lead plaintiff status, emphasizing the urgency of protecting shareholder rights and the potential for recovery in light of the allegations.
- No Cost Participation: Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress, with no costs or obligations involved, ensuring that investors stay informed throughout the litigation process.
See More
Reminder of Shareholder Class Action Lawsuits
- ADMA Lawsuit Details: The class action lawsuit against ADMA Biologics, Inc. alleges that the company made materially false or misleading statements between August 9, 2024, and March 25, 2026, leading to investor losses, with a deadline of August 10, 2026, for investors to apply as lead plaintiffs to protect their rights.
- Erasca Case Overview: The shareholder class action against Erasca, Inc. claims that the company failed to disclose material facts related to ERAS-0015 from January 14, 2025, to April 26, 2026, with a similar deadline of August 10, 2026, for investors to seek lead plaintiff status for legal recourse.
- Nano-X Litigation Insights: The lawsuit against Nano-X Imaging Ltd. alleges false statements regarding operational efficiency and cash burn from March 31, 2025, to April 17, 2026, with a deadline of August 11, 2026, for investors to apply as lead plaintiffs to safeguard their interests.
- Law Firm Credentials: Holzer & Holzer, LLC, recognized as a top-rated securities litigation firm from 2021 to 2025, focuses on vigorous representation of shareholders, having recovered hundreds of millions for victims of fraud and corporate misconduct since its inception in 2000.
See More
Class Action Filed Against Erasca, Inc. by Shareholders
- Class Action Initiated: Robbins LLP has announced a class action lawsuit on behalf of investors who purchased Erasca, Inc. (NASDAQ:ERAS) securities between January 14, 2025, and April 26, 2026, alleging that the company misled investors regarding its business prospects, potentially leading to shareholder losses.
- Allegations of False Statements: The complaint claims that during the class period, Erasca made false and/or misleading statements and failed to disclose material facts, including that the preclinical data for ERAS-0015 was based on improper comparisons, risking patent and trade secret violations, which could harm the company's reputation.
- Stock Price Decline Reaction: Following the disclosure on April 27, 2026, that Erasca received a legal letter from RevMed, the stock price plummeted from $21.49 per share on April 24, 2026, to $19.15 per share, indicating heightened market concerns about the company's future.
- Legal Follow-Up Actions: Investors are eligible to participate in the class action, with Robbins LLP offering contingency fee representation, meaning shareholders incur no costs to participate, demonstrating the firm's commitment to protecting shareholder rights.
See More
Class Action Lawsuit Announced Against Erasca, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Erasca (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, with a deadline for lead plaintiff applications set for August 10, 2026, highlighting the urgency and significance of the case.
- Potential Compensation Opportunity: Eligible Erasca shareholders may receive compensation without any out-of-pocket costs through a contingency fee arrangement, which reduces the financial burden on investors and encourages broader participation in the lawsuit.
- Legal Violation Allegations: The lawsuit alleges that Erasca, along with its CEO and CFO, violated federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, throughout the class period, potentially leading to investor losses.
- Market Reaction and Impact: As details of the lawsuit emerge, Erasca's market credibility may be undermined, leading to decreased investor confidence in the company's future and potentially exerting negative pressure on its stock price, reflecting the legal risks that threaten the company's operations.
See More
Class Action Lawsuit Announced for Erasca, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Erasca (NASDAQ:ERAS) common stock between January 14, 2025, and April 26, 2026, with a deadline of August 10, 2026, for those wishing to serve as lead plaintiff, potentially allowing for compensation.
- Legal Violations Allegations: The lawsuit alleges that Erasca, along with its CEO and CFO, violated federal securities laws by making false and misleading statements regarding its lead oncology drug candidate, ERAS-0015, throughout the class period, resulting in investor losses.
- Potential Compensation Mechanism: Investors joining the class action will not incur out-of-pocket fees, as attorney costs will be covered through a contingency fee arrangement, thereby reducing financial barriers and encouraging broader participation from affected investors.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its extensive experience and success in handling similar cases, which enhances investor confidence in their representation.
See More
Erasca Faces Class Action Lawsuit, Investors Can Claim Damages
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Erasca, Inc., aiming to recover damages for investors who purchased its securities between January 14, 2025, and April 26, 2026, highlighting potential legal risks facing the company.
- Allegations Overview: The complaint alleges that the defendants made false and misleading statements and failed to disclose material facts during the class period, which may have led investors to make erroneous decisions under conditions of asymmetric market information, thereby impacting their investment returns.
- Investor Participation Opportunity: Affected investors have until August 10, 2026, to apply to be lead plaintiffs, indicating that this case provides an avenue for investors to engage in legal proceedings and seek compensation, enhancing oversight of corporate governance.
- Fee Arrangement for Investors: Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis, meaning they will only charge fees after a successful claim, which reduces the financial burden on investors and encourages more victims to participate in the lawsuit.
See More
Erasca, Inc. Shareholder Class Action Notice Issued
- Class Action Notice: The Gross Law Firm has issued a notice to shareholders of Erasca, Inc. (NASDAQ:ERAS), encouraging those who purchased shares between January 14, 2025, and April 26, 2026, to contact the firm regarding potential lead plaintiff appointment for recovery.
- Allegations Overview: The complaint alleges that during the class period, defendants made materially false and/or misleading statements and failed to disclose that ERAS-0015's preclinical data was improperly compared to Revolution Medicines, Inc., risking patent violations and impacting investor trust and stock performance.
- Critical Deadline: Shareholders must register by August 10, 2026, to seek lead plaintiff status, emphasizing the urgency of protecting shareholder rights and the potential for recovery in light of the allegations.
- No Cost Participation: Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress, with no costs or obligations involved, ensuring that investors stay informed throughout the litigation process.
See More
Reminder of Shareholder Class Action Lawsuits
- ADMA Lawsuit Details: The class action lawsuit against ADMA Biologics, Inc. alleges that the company made materially false or misleading statements between August 9, 2024, and March 25, 2026, leading to investor losses, with a deadline of August 10, 2026, for investors to apply as lead plaintiffs to protect their rights.
- Erasca Case Overview: The shareholder class action against Erasca, Inc. claims that the company failed to disclose material facts related to ERAS-0015 from January 14, 2025, to April 26, 2026, with a similar deadline of August 10, 2026, for investors to seek lead plaintiff status for legal recourse.
- Nano-X Litigation Insights: The lawsuit against Nano-X Imaging Ltd. alleges false statements regarding operational efficiency and cash burn from March 31, 2025, to April 17, 2026, with a deadline of August 11, 2026, for investors to apply as lead plaintiffs to safeguard their interests.
- Law Firm Credentials: Holzer & Holzer, LLC, recognized as a top-rated securities litigation firm from 2021 to 2025, focuses on vigorous representation of shareholders, having recovered hundreds of millions for victims of fraud and corporate misconduct since its inception in 2000.
See More
Class Action Filed Against Erasca, Inc. by Shareholders
- Class Action Initiated: Robbins LLP has announced a class action lawsuit on behalf of investors who purchased Erasca, Inc. (NASDAQ:ERAS) securities between January 14, 2025, and April 26, 2026, alleging that the company misled investors regarding its business prospects, potentially leading to shareholder losses.
- Allegations of False Statements: The complaint claims that during the class period, Erasca made false and/or misleading statements and failed to disclose material facts, including that the preclinical data for ERAS-0015 was based on improper comparisons, risking patent and trade secret violations, which could harm the company's reputation.
- Stock Price Decline Reaction: Following the disclosure on April 27, 2026, that Erasca received a legal letter from RevMed, the stock price plummeted from $21.49 per share on April 24, 2026, to $19.15 per share, indicating heightened market concerns about the company's future.
- Legal Follow-Up Actions: Investors are eligible to participate in the class action, with Robbins LLP offering contingency fee representation, meaning shareholders incur no costs to participate, demonstrating the firm's commitment to protecting shareholder rights.
See More
Class Action Lawsuit Announced Against Erasca, Inc.
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Erasca (NASDAQ: ERAS) common stock between January 14, 2025, and April 26, 2026, with a deadline for lead plaintiff applications set for August 10, 2026, highlighting the urgency and significance of the case.
- Potential Compensation Opportunity: Eligible Erasca shareholders may receive compensation without any out-of-pocket costs through a contingency fee arrangement, which reduces the financial burden on investors and encourages broader participation in the lawsuit.
- Legal Violation Allegations: The lawsuit alleges that Erasca, along with its CEO and CFO, violated federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, throughout the class period, potentially leading to investor losses.
- Market Reaction and Impact: As details of the lawsuit emerge, Erasca's market credibility may be undermined, leading to decreased investor confidence in the company's future and potentially exerting negative pressure on its stock price, reflecting the legal risks that threaten the company's operations.
See More
